Serous ovarian tumors of low malignant potential (SLMP)--also called borderline tumors of the ovary--represent a heterogeneous group of ovarian epithelial neoplasms. In general, this tumor type ...

Ovarian cancer is the deadliest gynecologic malignancy globally and is increasing in incidence and mortality with currently more than 300,000 new cases and 200,000 deaths annually, according to data ...

Researchers at Peter Mac have uncovered potential new heredity genes that might be responsible for causing one of the most ...

Avutometinib and defactinib target KRAS-mutated recurrent low-grade serous ovarian cancer, potentially becoming the first FDA-approved treatment for this specific cancer type. The NDA is supported by ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 21.25%, which has investors questioning if this is right time ...

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) had its price target decreased by UBS Group from $5.00 to $2.20 in a research report released on Tuesday,Benzinga reports. UBS Group currently has ...

Forstner R. Early detection of ovarian cancer. Eur Radiol. 2020 Oct;30(10):5370-5373. doi: 10.1007/s00330-020-06937-z. Epub 2020 May 28. PMID: 32468105; PMCID: PMC7476911. Sans M, Gharpure K, ...

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer. In the cancer world — or anywhere — the ability to ...

"We ended 2024 having made tremendous progress across our pipeline programs, including FDA acceptance of our NDA with ...

The FDA accepted and granted priority review to an NDA for avutometinib plus defactinib in recurrent KRAS-mutated low-grade serous ovarian cancer. The FDA accepted and granted priority review to the ...

It can be concluded that ascites is an independent risk factor for the recurrence of MBOTs. Ovarian borderline tumors include mucinous, serous, endometrioid, clear cell, Brenner tumor and other ...